Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
Jonathan Webster(Johns Hopkins University), Ivana Gojo(Johns Hopkins University), Marlise R. Luskin(Dana-Farber Cancer Institute), Amy E. DeZern(Johns Hopkins University), Leo Luznik(Johns Hopkins University), Gabrielle T. Prince(Johns Hopkins University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Mark J. Levis(Sidney Kimmel Cancer Center), Amanda L. Blackford(Johns Hopkins University), Howard Streicher(National Cancer Institute), Elad Sharon(National Cancer Institute)
Cited by 50
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595